This Monday the biotech company announced that it is working with the US government to achieve this goal.
2 min read
Human VS coronavirus. Pharmacist Johnson Johnson (JJ) announced that it plans to start human clinical trials of its COVID-19 vaccine in September. The goal of the firm is that the medicine can be used in early 2021.
On Monday, March 30, the company reported that it is working on the project with the Advanced Biomedical Research and Development Authority ( Barda , for its acronym in English). He also said that he reached an agreement with the US government for a billion dollars to finance research, development and testing.
The pharmacist explained that if the vaccine works and is approved, it will use all its global manufacturing capacity to produce it quickly. However, Paul Stoffels, head of scientific research at JJ, told Reuters that the company must strengthen its manufacturing capacity immediately even if it is not certain that the vaccine will work. To do this they will build a plant in the United States.
According to Stoffels, the formula against COVID-19 is based on the same technology they used in their Ebola vaccine, which has already been tested in people and that the biotechnology firm considers safe.
Johnson Johnson is currently testing the vaccine in animals, however, they plan to start human clinical trials in September of this year 2020.